Atrial Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Biovalve Implantation "CAREAVR"


Phase N/A Results N/A

Trial Description

The primary purpose of the FIN-bioAVR registry is to assess the incidence of AF, strokes and major bleeding events in patients undergoing aortic valve replacement. This retrospective multicenter registry will include 850 patients with aortic valve replacement using bioprosthesis.


Trial Design

  • Observation: Cohort
  • Perspective: Retrospective
  • Sampling: Non-Probability Sample

Trial Population

All-comers design of patients undergoing aortic valve bioprosthesis implantation


Type Measure Time Frame Safety Issue
Primary Stroke 10 years Yes
Primary Mortality 10 years Yes
Primary atrial fibrillation 10 years Yes
Primary major bleeding 10 years Yes